The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials.

ABSTRACT:

Background

Concerns have emerged regarding the oncogenic potential of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors, particularly in relation to gynecologic malignancies. To date, no consensus has been reached on regimen-specific risks. This network meta-analysis (NMA) evaluated and compared the incidence of gynecologic tumors associated with various GLP-1 receptor agonists and SGLT2 inhibitors.

Methods

Following a Cochrane-recommended confirmatory approach, we conducted a frequentist-based NMA using data from randomized controlled trials (RCTs) including female participants. Systematic searches of major databases were conducted through March 3, 2025. The primary outcome was the incidence of gynecologic tumors; drop-

SUBMITTER: Tseng PT 

PROVIDER: S-EPMC12661836 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature